Please provide your email address to receive an email when new articles are posted on . An FDA advisory panel voted 0-15 against approving an interatrial shunt to improve symptoms and prognosis in ...
FDA advisors on Wednesday will deliberate on whether shunt therapy still has a narrow path forward in heart failure after a disappointing pivotal trial. In its premarket approval application for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results